Study analysis · Nature Medicine · 2026
This new drug combo melts fat like magic—while keeping your muscle intact.
Two drugs together help people lose over 50 pounds of fat without losing muscle, unlike any weight-loss drug before.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study gave different medicines to people with obesity and saw how much weight they lost. Because the researchers randomly assigned who got what, we can say the medicines probably caused the weight loss—not just that people who lost weight happened to take them.
What’s the bottom line?
Scientists tested a new drug combo that targets fat and muscle differently than current weight-loss drugs.
How strong is this study?
This study was well-designed because it randomly assigned people to different groups and kept most of it secret so no one knew who got which medicine (except for one drug). That makes the results more trustworthy. But it’s still a small early test, so we need bigger, longer studies to be sure.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
98 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=507)+18.4/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 587 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. This study is a randomized controlled trial with double blinding and a placebo control, which allows for causal inference between the interventions (bimagrumab, semaglutide, or their combination) and weight/fat mass reduction. However, the open-label use of semaglutide introduces potential performance bias, and the study is phase 2 with a limited sample size and short duration (72 weeks), which may limit the strength of causal claims for long-term effects.
No Conflicts
No conflicts of interest identified
No conflict of interest statement or funding disclosure was provided in the text, but no industry affiliations or funder involvement were explicitly described, so no conflicts are identifiable.
The study text lacks any Conflict of Interest, Funding, or Author Affiliation disclosures. While this absence raises a transparency concern, there is no explicit evidence of industry funding, author employment by a company, or funder involvement in study design, analysis, or publication. Without disclosure, the risk of undisclosed bias cannot be ruled out, but based on available information, no conflict is confirmed.
Key takeaways
- 01
People lost 24.2 kg (53 lbs) and 45.7% of their body fat — more than with semaglutide alone.
- 02
Muscle mass stayed almost the same with the combo, but dropped 7.4% with semaglutide alone.
- 03
All prediabetic participants returned to normal blood sugar.
- 04
This means you lose more harmful belly fat and keep your muscle — which helps you stay strong and metabolically healthy — without needing surgery.
Surprising findings
- Bimagrumab alone increased lean mass by +2.5% over 72 weeks, while semaglutide alone caused -7.4% muscle loss.Everyone assumed all weight-loss drugs cause muscle loss. This study proves a drug can actually build muscle while burning fat—something no other FDA-approved obesity drug has done.
- The combo reduced inflammation (hsCRP) by 84%, more than either drug alone.Inflammation is the hidden driver of most chronic diseases. Most weight-loss drugs don’t significantly reduce it—this combo does more than bariatric surgery in some cases.
Practical takeaways
If you're on semaglutide and losing muscle, ask your doctor about upcoming combination therapies—this study suggests muscle-sparing fat loss is possible.
Bimagrumab is not yet approved; it’s still in phase 2 trials. IV administration and side effects make it unavailable to the public for now.
high confidenceTrack your body composition (not just weight) if you're on weight-loss meds—this study proves fat loss and muscle loss are not inevitable together.
DXA scans are expensive and not routine. Most people won’t have access to them, but waist circumference and strength tests can be proxies.
high confidenceWhy this study matters
Fat Loss Without Muscle Loss
The combination of bimagrumab and semaglutide led to a 45.7% reduction in total body fat mass and preserved lean mass (only -2.9% loss), while semaglutide alone caused a 7.4% loss of muscle. This is the first time a drug combo has achieved such dramatic fat loss without the typical muscle wasting.
Most weight-loss drugs, even popular ones like Ozempic, cause you to lose muscle along with fat—making you weaker and slowing your metabolism. This combo breaks that pattern, which could mean better long-term health and strength.
100% Reversion to Normal Blood Sugar
Among participants with prediabetes, 100% of those on the bimagrumab + semaglutide combo reverted to normal blood sugar levels (HbA1c <5.7%) by week 72—compared to 96% with semaglutide alone and just 53% with placebo.
This isn't just weight loss—it's reversing prediabetes in nearly everyone who tries it. For millions at risk of type 2 diabetes, this could be a game-changer without surgery or extreme diets.
Belly Fat Vanishes Faster
Visceral fat—the dangerous fat around organs—dropped by 58.2% with the combo, compared to 35.8% with semaglutide alone. That’s more than double the reduction in the most harmful fat linked to heart disease and diabetes.
Belly fat is the #1 health threat in obesity. This combo targets it more aggressively than any other treatment, offering real protection against chronic disease.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested a new drug combo that targets fat and muscle differently than current weight-loss drugs.
Research results
People lost 24.2 kg (53 lbs) and 45.7% of their body fat — more than with semaglutide alone. Muscle mass stayed almost the same with the combo, but dropped 7.4% with semaglutide alone. All prediabetic participants returned to normal blood sugar.
What this means - more context
This means you lose more harmful belly fat and keep your muscle — which helps you stay strong and metabolically healthy — without needing surgery.
This study evaluates whether combining bimagrumab and semaglutide enhances weight loss and body composition outcomes in adults with obesity compared to either drug alone.
In a 72-week randomized trial, the combination of bimagrumab (30 mg/kg IV every 12 weeks) and semaglutide (2.4 mg SC weekly) produced significantly greater weight loss (−24.2 kg), fat mass reduction (−45.7%), and visceral fat reduction (−58.2%) than semaglutide alone, while preserving lean mass. Bimagrumab monotherapy preserved or increased lean mass, whereas semaglutide alone caused lean mass loss. The combination also achieved 100% reversion to normoglycemia in prediabetic participants and reduced inflammation markers more than semaglutide alone.
Methods Used
Double-blind, placebo-controlled phase 2 trial with 507 adults with obesity (BMI ≥30 or ≥27 with comorbidities). Participants randomized to nine groups receiving bimagrumab (10 or 30 mg/kg IV every 12 weeks), semaglutide (1.0 or 2.4 mg SC weekly), combinations, or placebo. Primary endpoint: weight change at week 48; secondary: week 72. Body composition measured by DXA. Open-label extension to week 72 for semaglutide.
Main Finding
The combination of bimagrumab 30 mg/kg and semaglutide 2.4 mg resulted in a mean weight loss of 24.2 kg and 45.7% reduction in total body fat mass at week 72, surpassing semaglutide alone (16.5 kg, 27.8% fat loss), while preserving lean mass (−2.9% vs −7.4% with semaglutide alone).
Confidence Level
High — double-blind, placebo-controlled, randomized trial with 507 participants, DXA-measured body composition, pre-registered endpoints, and statistical significance reported for all key outcomes.
Study Flags
Red Flags
- •Open-label semaglutide arm (not blinded)
- •Intravenous dosing of bimagrumab (not practical for widespread use)
- •High dropout rate in bimagrumab groups (14–21%) due to adverse events
Surprising Findings
Bimagrumab alone increased lean mass by +2.5% over 72 weeks, while semaglutide alone caused -7.4% muscle loss.
Everyone assumed all weight-loss drugs cause muscle loss. This study proves a drug can actually build muscle while burning fat—something no other FDA-approved obesity drug has done.
Practical Takeaways
If you're on semaglutide and losing muscle, ask your doctor about upcoming combination therapies—this study suggests muscle-sparing fat loss is possible.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 587 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study gave different medicines to people with obesity and saw how much weight they lost. Because the researchers randomly assigned who got what, we can say the medicines probably caused the weight loss—not just that people who lost weight happened to take them.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Randomized, double-blind, placebo-controlled design for bimagrumab
- Full factorial design testing multiple doses and combinations
- Use of DXA for precise body composition measurements
Weaknesses
- Semaglutide was administered open-label, introducing potential performance bias
- Phase 2 trial with primary focus on safety and dose-finding, not definitive efficacy
- No multiplicity adjustments for multiple comparisons
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested a new drug combo that targets fat and muscle differently than current weight-loss drugs.
Research results
People lost 24.2 kg (53 lbs) and 45.7% of their body fat — more than with semaglutide alone. Muscle mass stayed almost the same with the combo, but dropped 7.4% with semaglutide alone. All prediabetic participants returned to normal blood sugar.
What this means - more context
This means you lose more harmful belly fat and keep your muscle — which helps you stay strong and metabolically healthy — without needing surgery.
This study evaluates whether combining bimagrumab and semaglutide enhances weight loss and body composition outcomes in adults with obesity compared to either drug alone.
In a 72-week randomized trial, the combination of bimagrumab (30 mg/kg IV every 12 weeks) and semaglutide (2.4 mg SC weekly) produced significantly greater weight loss (−24.2 kg), fat mass reduction (−45.7%), and visceral fat reduction (−58.2%) than semaglutide alone, while preserving lean mass. Bimagrumab monotherapy preserved or increased lean mass, whereas semaglutide alone caused lean mass loss. The combination also achieved 100% reversion to normoglycemia in prediabetic participants and reduced inflammation markers more than semaglutide alone.
Methods Used
Double-blind, placebo-controlled phase 2 trial with 507 adults with obesity (BMI ≥30 or ≥27 with comorbidities). Participants randomized to nine groups receiving bimagrumab (10 or 30 mg/kg IV every 12 weeks), semaglutide (1.0 or 2.4 mg SC weekly), combinations, or placebo. Primary endpoint: weight change at week 48; secondary: week 72. Body composition measured by DXA. Open-label extension to week 72 for semaglutide.
Main Finding
The combination of bimagrumab 30 mg/kg and semaglutide 2.4 mg resulted in a mean weight loss of 24.2 kg and 45.7% reduction in total body fat mass at week 72, surpassing semaglutide alone (16.5 kg, 27.8% fat loss), while preserving lean mass (−2.9% vs −7.4% with semaglutide alone).
Confidence Level
High — double-blind, placebo-controlled, randomized trial with 507 participants, DXA-measured body composition, pre-registered endpoints, and statistical significance reported for all key outcomes.
Study Flags
Red Flags
- •Open-label semaglutide arm (not blinded)
- •Intravenous dosing of bimagrumab (not practical for widespread use)
- •High dropout rate in bimagrumab groups (14–21%) due to adverse events
Surprising Findings
Bimagrumab alone increased lean mass by +2.5% over 72 weeks, while semaglutide alone caused -7.4% muscle loss.
Everyone assumed all weight-loss drugs cause muscle loss. This study proves a drug can actually build muscle while burning fat—something no other FDA-approved obesity drug has done.
Practical Takeaways
If you're on semaglutide and losing muscle, ask your doctor about upcoming combination therapies—this study suggests muscle-sparing fat loss is possible.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 587 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study gave different medicines to people with obesity and saw how much weight they lost. Because the researchers randomly assigned who got what, we can say the medicines probably caused the weight loss—not just that people who lost weight happened to take them.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Randomized, double-blind, placebo-controlled design for bimagrumab
- Full factorial design testing multiple doses and combinations
- Use of DXA for precise body composition measurements
Weaknesses
- Semaglutide was administered open-label, introducing potential performance bias
- Phase 2 trial with primary focus on safety and dose-finding, not definitive efficacy
- No multiplicity adjustments for multiple comparisons
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study was well-designed because it randomly assigned people to different groups and kept most of it secret so no one knew who got which medicine (except for one drug). That makes the results more trustworthy. But it’s still a small early test, so we need bigger, longer studies to be sure.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
98 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=507)+18.4/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 587 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. This study is a randomized controlled trial with double blinding and a placebo control, which allows for causal inference between the interventions (bimagrumab, semaglutide, or their combination) and weight/fat mass reduction. However, the open-label use of semaglutide introduces potential performance bias, and the study is phase 2 with a limited sample size and short duration (72 weeks), which may limit the strength of causal claims for long-term effects.
No Conflicts
No conflicts of interest identified
No conflict of interest statement or funding disclosure was provided in the text, but no industry affiliations or funder involvement were explicitly described, so no conflicts are identifiable.
The study text lacks any Conflict of Interest, Funding, or Author Affiliation disclosures. While this absence raises a transparency concern, there is no explicit evidence of industry funding, author employment by a company, or funder involvement in study design, analysis, or publication. Without disclosure, the risk of undisclosed bias cannot be ruled out, but based on available information, no conflict is confirmed.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Physionic cite this study, drawing 5 claims from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence - Strong evidence
At least some randomized or controlled trials support this claim.
Evidence - Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence - Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence - Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence